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Resumo 
 
O vírus da imunodeficiência humana tipo 1 (VIH-1) é um vírus altamente patogénico e evasivo para o 
qual ainda não foi desenvolvida uma cura. A maioria dos fármacos antirretrovirais desenvolvidos 
contra esta infeção tem como alvo enzimas chave do seu ciclo replicativo, como a transcriptase 
reversa, integrase e protease. Um processo crucial na infeção pelo VIH é a fusão das membranas 
viral e do hospedeiro, pelo que o desenvolvimento de uma nova classe de antirretrovirais, os 
inibidores de fusão, apresenta uma grande vantagem face aos fármacos comummente usados na 
terapêutica, uma vez que estes atuam antes da libertação do genoma viral nas células do hospedeiro. 
Em estudos anteriores foi reportado que a atividade antiviral de péptidos inibidores de VIH-1 é 
amplificada pela conjugação com colesterol e polietilenoglicol (PEG). Assim, o objetivo deste trabalho 
é a caracterização da interação de péptidos que derivam do enfuvirtide, pela conjugação com 
colesterol, ácido palmítico ou α-tocoferol como âncoras lipídicas e PEG como espaçador, com 
sistemas membranares modelo e células sanguíneas humanas. 
Recorrendo a metodologias de espectroscopia de fluorescência, incluindo ensaios de partição e de 
extinção de fluorescência, demonstrou-se que a conjugação com porções lipídicas potencia a 
interação dos péptidos com membranas de diferentes composições lipídicas. Foi também averiguada 
a localização dos péptidos na membrana utilizando sondas lipofílicas, verificando-se que os péptidos 
conjugados se encontram numa posição mais superficial do que o não conjugado.  
A avaliação de alterações do potencial de dipolo da membrana permitiu verificar que os péptidos 
conjugados apresentam uma maior afinidade para membranas ricas em colesterol, assim como para 
células sanguíneas, contrariamente ao péptido não conjugado. 
De modo geral, os resultados obtidos indicam que um balanço entre a afinidade para a membrana e a 
exposição dos péptidos é essencial para o aumento da atividade antiviral dos mesmos. Assim, a 
adição de frações lipídicas a um inibidor de fusão reconhecido poderá ser uma estratégia promissora 
no combate à infeção por VIH-1. 
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Abstract 
 
The human immunodeficiency virus type 1 (HIV-1) is a highly pathogenic and evasive virus, for which 
no cure has yet been achieved. The majority of the antiretroviral drugs developed over the years 
against this infection target key enzymes in HIV life cycle, such as reverse transcriptase, integrase 
and protease. Fusion of viral and host cell membranes is a crucial step in virus infectivity; therefore, 
the development of viral entry inhibitors has great advantages over conventional drugs, since they 
prevent the release of the viral content into the host cell. Previous studies showed that the antiviral 
activity of HIV-1 inhibitor peptides is increased by the addition of cholesterol and polyethylene glycol 
(PEG). The aim of the present work is to characterize the interaction of enfuvirtide derived molecules 
by conjugation with cholesterol, palmitic acid or α-tocopherol as lipid anchors and PEG as spacer, with 
biomembrane model systems and human blood cells. 
Fluorescence spectroscopy methodologies, including membrane partition and fluorescence quenching 
assays, demonstrated that conjugation with lipids increases the peptides ability to interact with 
membranes of different compositions. In addition, the depth of peptide insertion into the membrane 
was assessed using lipophilic probes, revealing that the conjugated peptides are located in a more 
shallow position than the unconjugated one. Moreover, dipole potential assays showed that 
conjugated peptides exhibit a higher affinity towards cholesterol-rich membranes, as well as human 
blood cells, than the unconjugated peptide. 
Altogether, the obtained results indicate that a proper balance between membrane affinity and peptide 
exposure is required in order to enhance antiviral activity. Therefore, the addition of lipid moieties to an 
established fusion inhibitor such as enfuvirtide can be a promising strategy against HIV-1. 
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1.1. HIV: origin and diversity 
Human immunodeficiency virus (HIV) is the causative agent of the acquired immunodeficiency 
syndrome (AIDS), one of the most extreme cases of immune suppression caused by a pathogen 
(Murphy, 2011). Although the earliest documented case of HIV infection has been reported in samples 
of serum and lymph node biopsy from the present Democratic Republic of Congo, stored in 1959 and 
1960, respectively (Worobey et al., 2008; Zhu et al., 1998), it was only in 1981 that AIDS was officially 
recognized; as an unusual pattern of symptoms observed in a small group of previously healthy 
homosexual men in USA (Gottlieb et al., 1981). Soon after, AIDS cases were reported in other groups, 
including intravenous drug users and hemophiliacs (Davis, 1983; Masur et al., 1981). HIV was 
identified and isolated for the first time in 1983 (Barré-Sinoussi et al., 1983), being consider as the 
causative agent of AIDS (Coffin et al., 1986). 
Since the beginning of HIV epidemic, nearly 75 million people have been infected, with an outcome of 
about 36 million deaths. By the end of 2013, the United Nations Programme on AIDS (UNAIDS)/World 
Health Organization (WHO) epidemic update estimated 35.0 million (33.2 – 37.2 million) people were 
living with HIV, wherein 2.1 million (1.9 – 2.4 million) were newly infected people, and 1.5 million (1.4 – 
1.7 million) died due to AIDS (UNAIDS, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human immunodeficiency viruses belong to the Lentivirus genus, Retrovididae family and comprise 
two types of virus: HIV-1 and HIV-2. Although AIDS can be caused by both viruses, their origin and 
gene sequence differ. HIV-1 is the most virulent specie and progresses more rapidly to AIDS than 
HIV-2 (Weiss, 2000).  
HIV and their lineages derived from multiple and independent zoonotic transmissions, i.e. cross-
species transmissions, of simian immunodeficiency virus (SIV) from nonhuman primates into human in 
West and Central Africa; HIV-1 derived from the chimpanzee, Pan troglodytes, whereas HIV-2 from 
Figure 1.1 - Geographic distribution of adults and children estimated to be 
living with HIV in 2013.  
Worldwide, 35.0 million people were living with HIV at the end of 2013 (UNAIDS, 2014). 
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the sooty mangabey, Cercocebus atys. HIV-2 is endemic in West Africa, however the virus’ 
prevalence spread to Europe (especially Portugal) and India. The zoonotic transmissions by 
chimpanzees led to several HIV-1 lineages, groups M, N, O and P. Group M (Major/Main), which 
include various subtypes, is the most common and is responsible for the HIV-1 worldwide pandemic 
(Hemelaar, 2012; Reeves & Doms, 2002). A tremendous genetic variability, due to high mutations and 
recombinant rates of the reverse transcriptase enzyme which lacks a proof-reading mechanism, and 
high rates of virus replication are crucial factors in the worldwide spread of HIV, causing the virus to be 
highly adaptable to new hosts and selection pressures (Hemelaar, 2013). 
 
1.2. HIV transmission and progression of disease 
HIV infection takes place when body fluids are transferred from an infected person to an uninfected 
one. The virus can be transmitted through contaminated blood products (injection, blood 
transfusion/organ transplant), vertically (from mother to child) in pregnancy, birth or breastfeeding and, 
most frequently, through sexual activity (Murphy, 2011).  
Unlike several other viruses, HIV infection rarely leads to an immune response that prevents the 
ongoing virus replication; however, HIV does not cause AIDS immediately (Murphy, 2011). In the 
acute infection phase, within 2-6 weeks after HIV exposure, up to 80% people develop flu-like 
symptoms. This primary infection is clinically characterized by an increased viremia and a pronounced 
decrease in circulating CD4
+
 T cells, which are destroyed by the virus itself after replication, or by 
apoptosis. After this period, CD8
+
 T cells (a cytotoxic T cell that kills HIV-infected cells) are activated 
and the number of CD4
+
 cells begins to increase. The production of antibodies also takes place and 
their number rise to detectable levels whilst antigen levels becomes undetectable – seroconversion 
(Murphy, 2011). Besides the absence of symptoms, in the asymptomatic phase or clinical latency, the 
replication of the virus remains and the number of CD4
+
 cells decreases gradually. In untreated 
patients, this period has an average duration of 10 years. After this period, the illness progresses to 
AIDS, increasing the susceptibility to infection with opportunistic pathogens and the occurrence of 
tumors that usually do not affect people with a healthy immune system. Figure 1.2 summarizes the 
disease progression of untreated HIV infection. 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
1.3. HIV-1 structure and life cycle 
HIV-1 is an enveloped virus that infects CD4
+
 T cells, dendritic cells and macrophages (Murphy, 
2011). HIV virions are spherical particles with ≈ 100 nm in diameter (Sougrat et al., 2007), coated by a 
viral envelope membrane derived from the host cell plasma membrane, which covers and protects 
their capsid structures and the single-strand RNA copies (Figure 1.3). HIV-1 envelope glycoprotein 
(gene designation Env), whose function is to mediate binding and fusion of the viral membrane with 
the host cell membrane, is the only membrane protein encoded by the genomic RNA (Blumenthal et 
al., 2012; Podbilewicz, 2014). Env is first synthesized in the endoplasmic reticulum (ER) as a 
precursor protein termed gp160. After glycosylation in the Golgi apparatus, the protein is cleaved by 
the cellular protease furin into two subunits: a surface subunit (gp120) and a transmembrane subunit 
(gp41) (Hallenberger et al., 1992) that remain noncovalently associated, comprising a trimer of 
heterodimers. These glycoproteins are the main targets of HIV-1 neutralizing antibodies that, through 
selection, developed many mechanisms to evade the host immune response, making them the most 
variable proteins of HIV-1 (Burton et al., 2004; Wyatt, 1998). 
 
 
 
 
 
Figure 1.2 - The typical profile of untreated infection with HIV. 
The acute phase occurs 2–6 weeks after infection and is marked by high levels of virus in the 
bloodstream. In the asymptomatic phase, an adaptive immune response follows the acute phase, 
controlling it and restoring CD4
+
 T cells levels; however, without the complete removal of the virus. The 
symptomatic phase occurs as the CD4
+
 T cells count falls to 500 cells.μL
-1
, when opportunistic infections 
become more frequent. At a count of CD4
+
 T cells bellow 200 cells.μL
-1
 the patient is said to have AIDS 
(Murphy, 2011). 
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Each gp120 subunit contains an inner domain with five highly conserved regions, which are crucial to 
virus-cell attachment, and an outer domain with surface-exposed hypervariable loops (Figure 1.4), 
which are involved in immune evasion as they are a constantly moving target for the host’s immune 
system (Wilen et al., 2012). 
An ectodomain (extracellular domain), a transmembrane domain (TM) and an endodomain 
(intracellular domain) compose each gp41 subunit. The latter, also referred as, cytoplasmic tail (CT) 
plays a role in packaging, infectivity and cell pathogenicity (Yang et al., 2010). The transmembrane 
domain is responsible for Env’s anchorage in the viral membrane (Wilen et al., 2012). The ectodomain 
has a hydrophobic fusion peptide (FP) located at the N-terminal, whose function is to insert into the 
host membrane, and two heptad repeat regions, closer to the N-terminal (NHR) or C-terminal (CHR) 
(Franquelim et al., 2011). A Trp-rich domain, the membrane proximal external region (MPER), where 
several antibodies bind, is located at the C-terminal, between the TM and the CHR, and also seems to 
play an important role during membrane fusion (Lorizate et al., 2008).  
 
 
 
 
 
 
Figure 1.3 - Schematic representation of HIV-1 virion. 
The trimeric gp120-gp41 complexes are embedded in the membrane. The cytoplasmic tail of 
gp41 interacts with p17, a viral protein that composes the matrix and surrounds the capsid. 
The capsid protein, p24, is organized into a cone shape ensuring the integrity of the viral 
genome. Two single-stranded RNA copies are surrounded by nucleocapsid proteins (in 
yellow) and enzymes essential to the development of the virion. Adapted from (Karlsson 
Hedestam et al., 2008).  
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Moreover, the genetic material of the virus is composed by two single-stranded RNA molecules 
surrounded by nucleocapsid proteins and enzymes that are required for the development of the virion, 
such as reverse transcriptase, protease and integrase, which are also in contact with HIV’s genome. 
This structure is enclosed in a cone-shaped capsid comprised by the viral protein p24. To ensure the 
integrity of the virion, the capsid is surrounded by a matrix of viral proteins (Karlsson Hedestam et al., 
2008). 
The HIV-1 replication cycle (Figure 1.5) can be divided into two phases, an early phase and a late one 
(Tözsér, 2003). The early phase begins with the attachment of the mature virion to the host cell 
membrane, leading to viral-cell membrane fusion, and entry of the cone-shaped capsid. At this stage, 
the viral RNA is released and, by reverse transcription, a double-stranded viral DNA is generated, 
which is then integrated into the host genome. In the late stage of the cycle, the viral DNA is 
transcribed into mRNA that encodes different viral proteins. At the end of this phase, the assembly of 
virion proteins and viral RNA takes place in the plasma membrane, and finally the immature virus exits 
the cell by a budding process followed by a protease-mediated maturation. 
 
 
Figure 1.4 - Structure of gp160. 
Gp160 comprises gp120 and gp41 (A). The homotrimer of 
gp120/gp41 heterodimers is associated with the viral membrane 
through the transmembrane region of gp41 (B). Gp120 has surface-
exposed hypervariable loops (C). Red bars represent disulfide 
bridges. (Source: http://pathmicro.med.sc.edu/lecture/hiv9.htm) 
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The research of HIV has been useful, not only for the understanding the nature of the disease, but 
also for prevention, diagnosis and treatment. Since HIV’s discovery as the causative agent of AIDS, 
the development of anti-HIV drugs has been the focus of intense research (De Clercq, 2013). As a 
consequence, many drugs are now available, but still no cure or vaccine was achieved. The majority 
of the approved antiretroviral drugs target three essential enzymes of the HIV life cycle: reverse 
transcriptase, integrase and protease (De Clercq, 2009). As reviewed by Adamson & Freed (2010), 
these drugs have significantly extended the life-expectancy of HIV patients. The combination of 
several antiretroviral drugs, known as highly active antiretroviral therapy (HAART), is considered the 
standard treatment for HIV patients. Despite having the advantage of combining multiple drugs, 
preventing HIV’s resistance to a single inhibitor, drug resistance can still emerge. As a consequence 
of this multi-drug resistance an alternative treatment, known as salvage therapy, is required. This will 
be more effective if new drugs are available.  
Even though HIV infections decreased by 38% since 2001 and the treatment cost is more affordable, 
and consequently a higher number of people are receiving HIV treatment, there are 22 million people 
to whom antiretroviral therapy is still inaccessible (UNAIDS, 2014). Therefore, the development of 
more potent and economically viable drugs is required. 
Figure 1.5 - Schematic representation of the HIV-1 cycle. 
The infection begins with the attachment (1) to the host cell, followed by viral-cell membrane fusion (2). The 
uncoating and release of the viral genome (3) facilitates reverse transcription (4). The pre-integration complex 
(PIC) is transported to the cell nucleus (5) and the viral genome is integrated into the host genome (6). The 
proviral transcription (7) generates mRNAs of different sizes that are exported (8) from the nucleus and serve 
as templates for protein production (9).The viral components are assembled (10) and, by a budding process 
(11), the immature virion is released (12). At this stage, the virion undergoes a protease-mediated maturation 
(13) (Engelman & Cherepanov, 2012).  
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1.3.1. HIV-1 entry and its inhibition 
As an enveloped virus, HIV-1 must transfer its genetic material across both the viral and host 
membranes to infect a cell (Doms & Trono, 2000). The attachment and viral fusion with host’s cell 
membrane are crucial steps in the HIV life cycle. The efficient blocking of these steps prevents the 
occurrence of the subsequent intracellular stages of the viral life cycle (Hollmann et al., 2013). 
HIV-1 entry into the host cell is a multi-step process that comprises attachment of the virus to the cell 
surface, receptor binding, co-receptor binding and membrane fusion (Tilton & Doms, 2010).  
The first step of HIV-1 entry is the binding of gp120 to the CD4 receptor of the host cells (Figure 1.6). 
Gp120 has high affinity towards the cell-surface receptor: nevertheless, this event is not sufficient to 
trigger membrane fusion (Klasse, 2012; Wilen et al., 2012). Therefore, gp120 must also bind to a co-
receptor in host’s membrane. There are two chemokine receptors that act as major co-receptors for 
viral entry, CCR5 and CXCR4, which use depends on the viral strain (Locher et al., 2005). The 
interaction of gp120 with the CD4 receptor causes conformational changes enabling the glycoprotein 
to bind to the co-receptor. At this stage, the hydrophobic N-terminal gp41 fusion peptide is exposed 
and interacts with the membrane of the host cell, into which it inserts, prompted by a tripled-stranded 
coiled-coil (Doms & Trono, 2000), formed by the NHR from each gp41 of the trimer. During membrane 
fusion both helical domains of the gp41, NHR and CHR, folds into each other in an antiparallel 
fashion, resulting in a highly stable structure named six-helix bundle (6HB). The 6HB structure brings 
the viral and cell membranes into close proximity, allowing membrane fusion and, consequently, the 
release of the viral content into the host cell (Wilen et al., 2012). 
 
 
Figure 1.6 - Entry mechanism of HIV-1. 
The viral envelope gp120 binds to CD4 receptor, inducing conformational changes that promote co-receptor 
binding. This engagement results in the exposure of the gp41 fusion peptide and its insertion into the target 
membrane. The formation of a hairpin-like structure, in which gp41 folds back on itself, brings the viral and cell 
membranes into close proximity and membrane fusion occurs. The bottom part of the figure displays gp41 alone; 
addition of the T20 peptide blocks membrane fusion (vd. infra). Adapted from (Doms & Trono, 2000). 
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Despite HAART’s efficiency at inhibiting HIV replication, reducing AIDS morbidity and mortality, it does 
not eradicate HIV infection (Tilton & Doms, 2010); patients require treatment indefinitely. As a result, 
long-term toxicity, drug-drug interactions and emergence of drug-resistance strains of HIV may arise, 
limiting treatment effectiveness. As a consequence, and also due to high costs of HAART, new 
strategies to inhibit viral replication have been investigated. 
Since HIV-1 entry is a multi-step process involving multiple interactions between Env and host 
proteins, each step of the process can be a target for entry inhibitors. This new class of antiretroviral 
can be divided into three categories: attachment and CD4 inhibitors, co-receptor inhibitors and fusion 
inhibitors (Wilen et al., 2012). Attachment inhibitors target the gp120-CD4 binding step by blocking the 
interaction between gp120 and the CD4 receptor, while antagonists of the co-receptors act on the 
binding step of gp120 to the co-receptor (CCR5 or CXCR4). Fusion inhibitors act on the               
gp41-mediated membrane fusion step (reviewed by Henrich & Kuritzkes 2013; Haqqani & Tilton 2013; 
Berkhout et al. 2012). 
Despite this promising approach in drug development against HIV-1, until now, only two entry 
inhibitors were approved by the USA Food and Drug Administration (FDA), and are currently clinically 
available; maraviroc, an inhibitor of the gp120 binding to the CCR5 co-receptor (Lieberman-Blum et 
al., 2008), and enfuvirtide (T20), a fusion inhibitor peptide that targets gp41 in its pre-hairpin 
conformation (Matthews et al., 2004).  
 
 
 
1.4. Fusion inhibitors 
The initial development of HIV-1 fusion inhibitors was based on the heptad repeat domains (HR) of 
gp41 (Jiang et al., 1993; Wild et al., 1992). The formation of the 6HB by the back-folding of gp41 NHR 
and CHR is a critical step for membrane fusion; after pore formation in its pre-bundle complex, this 
structure also stabilizes and expands the nascent fusion pore (Markosyan et al., 2003). Hence, the 
first strategy to suppress HIV-1 fusion was the use of synthetic peptides mimicking one of those 
domains. Peptides that mimic the NHR and CHR domains are known as N-peptides and C-peptides, 
respectively. These fusion inhibitors interact with gp41 domains interfering with the formation of the 
6HB, and preventing the expansion and stabilization of the fusion pore (Wilen et al., 2012). 
Fusion inhibitors can be divided into different classes according to their interaction with gp41 (Figure 
1.7). Class I fusion inhibitors are synthetic peptides that mimic the CHR domain of gp41 and act by 
competitively binding to NHR, thus preventing 6HB formation. C-peptides, such as enfuvirtide, T-1249, 
sifuvirtide and C34 belong to this class. Classes II and III include peptides that mimic the gp41 NHR 
domain, the N-peptides. These act by targeting the CHR region (class II) or by interspersing with the 
NHR region, preventing the trimerization of the NHR subunits (class III). Although peptides in these 
classes exhibit inhibitory activity against HIV, they are less potent than C-peptides, mainly due to their 
tendency to aggregate and low solubility, since N-peptides are rather hydrophobic (Berkhout et al., 
2012; Franquelim et al., 2011). Class IV comprises monoclonal antibodies that target the membrane  
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proximal region of gp41 (Reardon et al., 2014). Finally, class V includes peptides that target the gp41 
fusion peptide, preventing its insertion into the target membrane and subsequent membrane fusion. 
To this class belongs a natural antiviral peptide present in human blood, termed virus inhibitory 
peptide (VIRIP) (Münch et al., 2007). 
Additionally, new classes of fusion inhibitors that target the viral membrane were also reported: rigid 
amphipathic fusion inhibitors (RAFI) (St Vincent et al., 2010; Vigant et al., 2013), small lipophilic 
molecules such as LJ001 or JL103 (Vigant et al., 2013, 2014), or modified sterols as 25HC (Liu et al., 
2013). All these small molecules have the ability to modify biophysical properties of the membrane, 
preventing the fusion process. 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.7 - Classes of HIV-1 fusion inhibitors. 
Class I inhibitors mimic the gp41 CHR domain and bind to the NHR domain. Class II inhibitors mimic the NHR 
domain and bind to CHR. Class III inhibitors mimic the gp41 NHR domain, preventing the trimerization of 
NHR. In these three classes, the formation of the 6HB is prevented. Class IV inhibitors comprise antibodies 
that target the membrane proximal region, and in class V are comprised inhibitors that target the N-terminal 
fusion peptide of NHR. Adapted from (Steffen & Pöhlmann, 2010).  
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1.5. C-peptides: new strategies against HIV-1 fusion 
Structural analysis of the trimeric gp41 structure and understanding the CHR and NHR interaction 
enabled the development of peptides derived from the gp41 sequence towards HIV inhibition 
(Franquelim et al., 2011). The CHR region contains a pocket binding domain (PBD) complementary to 
deep hydrophobic pockets of the NHR core. Moreover, a HR core and a lipid binding domain (LBD) or 
tryptophan-rich domain (TRD) are also part of the CHR region. 
C34, a C-peptide with 34 amino acids, was used to determine the trimeric coiled-coil structure of gp41 
(Chan et al., 1997). Despite its high antiviral activity in vitro, C34 is not a good drug candidate due to 
its low solubility (Otaka et al., 2002) and other factors (some of them not totally understood), leading to 
low in vivo efficacy. 
Enfuvirtide (T20) is a synthetic polypeptide of 36 amino acids that is homologous to the CHR domain 
of gp41. The interaction between enfuvirtide and the virus is still not completely clear and is fairly 
complex. Some authors proposed that the mechanism of action by which enfuvirtide inhibits viral 
fusion is different from the one accepted for C34; enfuvirtide may target multiple sites in gp41 and 
gp120 (Liu et al., 2005, 2007; Veiga et al., 2004a). Still, currently the most accepted mechanism for 
enfuvirtide is the one described for C-peptides in general (Franquelim et al., 2011). As a class I fusion 
peptide, enfuvirtide engages in a coil-coil interaction with the gp41 NHR domain, thus blocking the 
6HB formation and membrane fusion (Matthews et al., 2004). However, enfuvirtide lacks the PBD 
region (Figure 1.8), important for high antiviral activity (Chan et al., 1998). There are other drawbacks 
to enfuvirtide: due to its peptide nature, it has a poor bioavailability (has to be administered 
subcutaneously) and is more sensitive to degradation while in circulation, its short half-life (≈ 4 h) 
requires more frequent injections that can cause injection site reactions for patients, rapid emergence 
of resistant strains, and high costs of production. This makes the long-term use of enfuvirtide 
problematic. For these reasons, enfuvirtide is primarily used in salvage therapy in patients where 
previous antiretroviral treatment has failed. Nevertheless enfuvirtide has many advantages: it has a 
potent antiviral effect in vitro and in vivo, low toxicity as it targets the protein of the virus instead of host 
cells, and it is effective against multi-drug resistant strains (Berkhout et al., 2012; De Clercq, 2009; 
Greenberg & Cammack, 2004; Matthews et al., 2004). 
 
 
 
12 
 
 
 
Based on the structural and functional information provided by C34 and enfuvirtide, new fusion 
peptides were developed. 
T-1249 is a second generation fusion inhibitor. This peptide has 39 amino acid residues and was 
designed based on HIV-1, HIV-2 and SIV sequences (Eron et al., 2004). Even though T-1249 
presented higher antiviral activity and a longer half-life than enfuvirtide, clinical development of this 
peptide was suspended due to problems in drug formulation (Martin-Carbonero, 2004). 
Three-dimensional structural information of HIV-1 gp41 allowed the development of another second-
generation fusion inhibitor, sifuvirtide. It is a 36 amino acid peptide engineered with different sequence 
and/or location in relation to C34, enfuvirtide and T-1249. In phase Ia clinical studies, sifuvirtide 
showed a higher potency and half-life in humans compared to enfuvirtide, enabling less clinical 
dosage and frequency of injections. Moreover, it showed to be highly effective against enfuvirtide-
resistant strains (He et al., 2008b). Sifuvirtide successfully completed Phase IIb clinical trials 
(http://fusogen.com/en/company-news/177). Although sifuvirtide appear to be a good candidate 
towards HIV-1 inhibition, there is a continuous search to optimize fusion inhibitor peptides.  
In 2001, a different approach was taken to overcome the drawbacks of enfuvirtide (Hildinger et al., 
2001), by expressing a membrane-anchored version of enfuvirtide on a T-cell helper line. It was 
shown that this modified peptide (a construct of enfuvirtide, a short linker and a transmembrane 
domain) exhibited more antiviral activity than the construct without the transmembrane domain. 
Additionally, mutations in the membrane-proximal region of enfuvirtide inactivated the free peptide, but 
did not have the same effect on the membrane-anchored version of enfuvirtide. These results suggest 
that binding the drug to the cell membrane has a positive effect on its efficiency. 
Based on this approach, a modified fusion peptide was developed to improve the antiviral activity of 
C34 by the addition of a cholesterol (Chol) moiety to its C-terminal (Ingallinella et al., 2009). It was 
Figure 1.8 - Characteristics of several C-peptides.  
Schematic representation of HIV-1 gp41 main domains; the relative position of the fusion peptide (FP), 
N-terminal heptad repeat domain (NHR), C-terminal heptad repeat domain (CHR) and transmembrane 
region (TM) are depicted. Several sequences of C-peptides were aligned, showing the pocket binding 
domain (PBD) and the lipid binding domain (LBP). Hydrophobic residues are represented in blue, non-
charged polar residues in green, and charged polar residues in red. Adapted from (Hollmann et al., 
2013). 
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hypothesized that using a cholesterol group as lipid anchor would be the most suitable approach due 
to the role of lipid rafts in HIV infection. Lipid rafts are microdomains within the lipid membrane, 
enriched in cholesterol and sphingolipids, where several transmembrane proteins and receptors are 
concentrated, including CD4, the main receptor for HIV infection (Aloia et al., 1988; Brügger et al., 
2006). Besides the high antiviral activity observed for C34-Chol, this peptide also presents an 
increased half-life in vivo (≈ 24 h) (Ingallinella et al., 2009). Moreover, due to its cholesterol moiety, 
C34-Chol is able to partition into lipid membranes, especially cholesterol-rich domains (Hollmann et 
al., 2013). The increased antiviral activity and improved pharmacokinetic properties, along with 
peptide accumulation at the site of action (Augusto et al., 2014; Hollmann et al., 2013; Ingallinella et 
al., 2009), make this approach a good strategy for the development of new drugs. 
While lipid conjugation is a preferential approach to improve peptide pharmacokinetics (Madsen et al., 
2007), the covalent attachment of a polyethylene glycol (PEG) polymer to proteins is the most well-
established strategy to prolong the half-life of a drug (Jevsevar et al., 2010). 
 
1.6. Objectives in the context of the state-of-art 
Despite major progresses in the development of new antiviral drugs, enfuvirtide still remains as the 
only class I fusion inhibitor peptide approved for the treatment of HIV by the USA Food and Drug 
Administration (FDA) and European Medicines Agency (EMA). In this context, and considering the 
advantage of the lesson of C34 peptide derivatization with PEG and cholesterol moieties, a new set of 
modified fusion inhibitors was designed: T20* (T20 or enfuvirtide with the additional GSGSGC 
residues on its C-terminal) was conjugated with different lipid moieties, namely cholesterol, palmitic 
acid (Palm) and α-tocopherol (Toco) as membrane anchors and a four residues PEG spacer in 
between the lipid and the peptide. As a result of this approach, 5 peptide derivatives were successfully 
synthetized and are the main focus of this work. The antiviral activity of these novel peptides showed 
higher antiviral activity than its parental T20*, being in this way promising candidates towards HIV 
inhibition.  
As previously pointed out, the interaction of the inhibitor peptides with membranes is a key factor in 
the characterization and unravelling of the mechanism of action of these fusion inhibitors. Taking this 
into consideration, the aim of this work was to evaluate the interaction of this family of enfuvirtide-
derived molecules with biomembrane model systems and human blood cells.  
Fluorescence spectroscopy methodologies were used to achieve these objectives, by the 
determination of the partition coefficient of the peptides to membranes with different compositions. A 
fluorescent probe, di-8-ANNEPS, was also used to evaluate peptides’ interaction with model 
membranes and human blood cells (erythrocytes and lymphocytes). Finally, in order to elucidate the 
in-depth location of the different peptides in the membrane, quenching assays using aqueous 
(acrylamide) and lipophilic (5NS and 16NS) quenchers were performed. 
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2.1. Materials 
 
T20* (MW = 4997.4 g/mol), T20*-Chol (MW = 5368.0 g/mol), T20*-PEG4-Chol (MW = 5615.3 g/mol), 
T20*-PEG4-Palm (MW = 5440.1 g/mol), T20*-Toco (MW = 5412.0 g/mol) and T20*-PEG4-Toco (MW = 
5659.3 g/mol) peptides were obtained on the context of a collaboration project with Prof. Matteo 
Porotto (Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of 
Cornell University, New York, USA). 
Human blood samples were obtained from healthy volunteer donors at Instituto Português do Sangue 
(IPS), Lisbon, under an institutional agreement between IPS and Instituto de Bioquímica from 
Faculdade de Medicina da Universidade de Lisboa, with their informed written consent. The samples 
were drawn to K3EDTA anticoagulant tubes (Vacuette, Greiner Bio-One, Kremsmünster, Austria) and 
processed shortly after. This study was approved by the joint Ethics Committee of Faculdade de 
Medicina da Universidade de Lisboa and Hospital de Santa Maria (Lisbon). 
POPC (1-palmitoyl-2-oleyl-sn-glycero-3-phosphocholine) and SM (egg sphingomyelin) were 
purchased from Avanti Polar Lipids (Alabaster, AL, USA). Acrylamide and HEPES (4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid) were obtained from Fluka (Buchs, Switzerland). 
KHCO3 (potassium hydrogencarbonate), EDTA (ethylenediaminetetraacetic acid), cholesterol, 
Pluronic-F127, ANS (8-anilino-1-naphthalenesulfonic acid ammonium salt), 5NS (5-doxyl-stearic acid) 
and 16NS (16-doxyl-stearic acid) were acquired from Sigma-Aldrich (St. Louis, MO, USA). The 
fluorescent probe di-8-ANEPPS (4-[2-[6-(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-
pyridinium) was purchased from Invitrogen - Molecular Probes (Eugene, OR, USA). Lymphoprep
TM
 
was obtained from Stemcell Technologies (Vancouver, BC, Canada). Chloroform, DMSO (dimethyl 
sulfoxide), methanol, NaCl (sodium chloride), NH4Cl (ammonium chloride) and L-Tryptophan were 
acquired from Merck (Darmstadt, Germany).  
HEPES buffer (HEPES 10mM pH 7.4 in NaCl 150 mM) was the working buffer used throughout the 
experiments. L-Tryptophan 500 µM stock solution was prepared in buffer, while ANS 2 mM and 
acrylamide 4 M solutions were prepared in ultrapure H2O. Stock solutions of the fluorescent probe di-
8-ANEPPS 1 mg/mL and the lipophilic quenchers 5NS and 16NS 70 mM were prepared in ethanol. All 
stock solutions were stored at 4 ºC, except 5NS and 16NS (stored at -20 ºC). 
 
 
2.2. Methods 
 
2.2.1. Peptides 
The peptides used in this work derive from enfuvirtide (T20), which amino acid sequence is 
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF. T20* and its derivatives have the same amino 
acid sequence, followed by 6 additional amino acid residues (GSGSGC), added before a lipid moiety - 
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cholesterol (Chol), palmitic acid (Palm) or α-tocopherol (Toco) - with or without a four unit polyethylene 
glycol (PEG) spacer in between, as presented in Figure 2.1. 
 
 
 
Stock solutions of each peptide, with a final concentration of 500 μM, were prepared in dimethyl 
sulfoxide (DMSO) and stored at 4 ºC. 
 
2.2.2. Biomembrane systems preparation 
Liposomes 
Different lipids such as POPC, Chol and SM were weighed to generate vesicles of diverse 
compositions: pure POPC, POPC:Chol (2:1) and POPC:Chol:SM (1:1:1). The lipids were dissolved in 
an organic solvent (POPC and POPC:Chol in chloroform and POPC:Chol:SM in a 
chloroform:methanol (12:1) mixture), and mixed in a round-bottom flask. A thin lipid film was formed by 
solvent evaporation using a gentle N2 (g) flow. In order to remove residual organic solvent and, 
therefore, obtain a completely dried film, the flask was connected to a vacuum pump overnight. The 
dried lipid film was hydrated with buffer (HEPES) and, at least, 8 freeze-thaw cycles were performed 
until the formation of a liposome suspension of multilamellar vesicles (MLV). Large unilamellar 
vesicles (LUV) were obtained by extrusion (Mayer et al., 1986), using a mini-extruder (Avanti Polar 
Lipids, Alabaster, AL, USA), 1001RN syringes (Hamilton, Reno, NV, USA) and 100 nm pore 
polycarbonate 10 mm diameter membranes (Nucleopore-Whatman, Kent, UK). LUV with, 
approximately, 100 nm of diameter were obtained. 
Figure 2.1 - Representation of enfuvirtide, T20* and its lipid derivatives. 
Non-charged polar residues are represented in green, charged polar residues in red and hydrophobic residues in 
blue, wherein the three tryptophan residues (W) are shown in black. 
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Biological samples 
Erythrocytes isolation  
Blood samples were centrifuged for 10 min at 1200 g (Sorvall TC6 Centrifuge, H400 rotor) to remove 
plasma and buffy-coat. Isolated erythrocytes were washed, at least twice with working buffer, and a 
100% hematocrit sample was obtained (Matos et al., 2010a). 
Peripheral blood mononuclear cells (PBMC) isolation  
PBMC were isolated from blood samples using a density gradient medium Lymphoprep
TM
. Samples 
were centrifuged for 30 min at 540 g, allowing the removal of plasma, isolation of buffy-coat containing 
the desired cells and keeping the erythrocytes’ pellet intact (Matos et al., 2010a). Isolated PBMC were 
washed at least twice with working buffer and an erythrocytes lysis buffer (157 mM NH4Cl, 10 mM 
KHCO3, EDTA 5%, pH 7.4) was used in order to prevent possible contaminations. In the washing 
steps, samples were centrifuged for 10 min at 100 g. 
 
2.2.3. Fluorescence spectroscopy measurements 
Peptide aggregation  
T20* derivatives, by being conjugated with lipid moieties, are prone to aggregation when in aqueous 
solutions; hence, protein aggregation was monitored by ANS fluorescence. ANS is an amphiphilic 
fluorescent probe sensitive to its microenvironment and is commonly used to evaluate the presence of 
hydrophobic pockets in proteins and peptides. The probe exhibits a low quantum yield (and therefore, 
low fluorescence emission) in aqueous solution; however, when located in a less polar environment, 
its quantum yield (and fluorescence intensity) increases, and its emission maximum shifts to lower 
wavelengths (Henriques et al., 2008). 
A solution containing 12.8 μM of ANS in HEPES buffer was titrated with a stock solution of each 
peptide to achieve a final concentration within the 0-8 μM range. ANS fluorescence emission spectra 
were obtained from 400 to 600 nm, with an excitation wavelength (λexc) of 369 nm, using an Edinburgh 
Instruments FLS920 Series fluorescence spectrophotometer (Livingston, UK). Excitation and emission 
bandwidths were set to 5 and 10 nm, respectively.  
 
Partition coefficient determination 
Fluorescence spectroscopy is a valuable and sensitive tool to assess the partition coefficient of a 
molecule. An alteration on a fluorescence property of a membrane probe or a difference in a 
fluorescence parameter such as quantum yield, fluorescence anisotropy or fluorescence lifetime of the 
partitioning molecule upon incorporation in the membrane, enables the determination of the partition 
coefficient.  
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The intrinsic fluorescence of T20* and its conjugates, as these peptides contain three tryptophan 
residues, allows the quantification of its membrane insertion. The fluorescence of this aromatic amino 
acid is strongly dependent of the physical properties of its micro-environment and can change 
significantly upon peptides’ insertion in the membrane. 
For each peptide, the partition coefficient between an aqueous and a lipid phase in equilibrium can be 
described as (Matos et al., 2010b; Santos, 2003): 
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where    and    are the moles of lipid and water and            and           are the moles of 
peptide in lipid and water, respectively. Under most experimental conditions, the quantity of peptide is 
considerably lower in both phases than the total quantities of water or lipid (              ), therefore 
this equation can by simplified to: 
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In most literature it is common to represent the partition coefficient as a function of the volumes of 
each phase (  ) instead of the water and lipid quantities: 
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This parameter, named the Nernst partition coefficient can be related with equation (2.2) by: 
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where    is the molar volume of water (   ) or lipid (   ). 
As mentioned before, the fluorescence intensity,  , can be measured as long as a peptide 
fluorescence parameter, such as the quantum yield, has a significant difference in the aqueous 
environment and the lipid membrane, and its partition coefficient can be determined measuring the 
tryptophan fluorescence intensity with a fixed concentration of peptide and an increasing lipid 
concentration ([ ]). These measurements usually give rise to a hyperbolic   vs. [ ] variation profile that 
can be fitted using: 
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Diverse membrane compositions, specifically POPC, POPC:Chol (2:1) and POPC:Chol:SM (1:1:1), 
were used to assess the peptides’ membrane partition coefficient. A fixed concentration of 10 μM of 
peptide in a HEPES buffer solution was titrated with a 15 mM LUV suspension, freshly prepared, 
yielding a final lipid concentration ranging from 0 to 5 mM. Preceding the fluorescence emission 
analysis, an incubation time of 10 min was used after each addition of LUV suspension, to stabilize 
peptides’ interaction with lipid membranes. The fluorescence emission spectrum of each peptide was 
recorded between 310 and 450 nm, considering that the maximum emission of the tryptophan residue 
in aqueous solution is 350 nm, and a λexc of 280 nm was used. The lipid titration was also performed 
on samples without peptide. Samples containing HEPES buffer and a tryptophan solution (30 μM) in 
HEPES buffer, both with DMSO as well, were used as a blank and control, respectively.  
The intensity data of the nonpartitioning Trp was used to correct the scattering effects resulting from 
the successive addition of LUV. The correction factor for each addition is as follows (Ladokhin et al., 
2000): 
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where          is the fluorescence intensity of the peptide,     the lipid concentration and     
      
and 
     the fluorescence intensity of the tryptophan residue in the absence and presence of the lipid, 
respectively. 
 
Membrane dipole potential assessment 
Cellular lipid bilayers have three types of electrostatic potentials associated to them: transmembrane 
potential, ΔΨ, as a result of an imbalance of charge and an electrical potential difference across the 
membrane by the selective transport of ions and, therefore, a difference in the ion concentration in 
both sides of the membrane; surface potential, ΨS, generated by the charged head-groups of 
phospholipids and the adsorbed ions at the interface, resulting in an accumulation of charges in the 
outer surface of the membrane; and dipole potential, Ψd, which arises from the orientation of dipole 
residues of lipids (polar head-groups and glycerol-ester regions) and water molecules hydrating the 
surface of the membrane (Matos et al., 2008; Wang, 2012). 
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Since the dipole potential originates from oriented dipoles in the membrane/water interface, 
macromolecules interacting with lipid membranes can cause a change in the potential by the 
destabilization of such organization and/or by the contribution of their own dipoles to the membrane 
dipole potential. Thus, monitoring dipole potential alterations is a useful tool to study membrane 
interactions with molecules, such as proteins and peptides, particularly if they are not intrinsically 
fluorescent. Moreover, this avoids the requirement to derivatize peptides and proteins, which can 
modify their structure and, consequently, the function of these molecules. This strategy is also 
advantageous on the study of cell systems, as the peptides’ intrinsic fluorescence is interfered by 
other cellular proteic components (Matos et al., 2010b; Wang, 2012). Regardless the intrinsic 
fluorescence of T20* and its conjugates, their interaction with membranes was also evaluated by 
alterations in the dipole potential.  
One of the fluorescent membrane probes described as sensitive to alterations in the dipole potential is 
di-8-ANEPPS (Gross et al., 1994). 
 
 
 
 
 
 
 
 
 
Figure 2.2 - Schematic representation of the three 
types of membrane potential. 
ΔΨ is the transmembrane potential, ΨS, the surface potential 
and Ψd is the dipole potential. Typical values of dielectric 
constant, ε, are given (Wang, 2012). 
Figure 2.3 - Structure of di-8-ANEPPS (blue) between 
phospholipids (black). 
Adapted from (Matos et al., 2008). 
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This probe consists in two aliphatic chains, facilitating its incorporation in the outer leaflet of the 
membrane, attached to a chromophore region (conjugated structure) that stays nearby the lipid head-
group region and senses the electric fields derived from the dipoles, acting as a reporter. This probe is 
believed to be electrochromic, i.e., a shift in the absorption and emission spectra occur under the 
influence of an electric field (Wang, 2012). A dual wavelength ratiometric measurement can be carried 
with the benefit of the signal being independent of probe or cell concentrations and avoiding 
photobleaching artifacts. Di-8-ANEPPS can only be used as a ratiometric probe of dipole potential if 
the measurements are based on excitation spectrum shifts (Vitha & Clarke, 2007). Thus, the excitation 
wavelengths of 455 and 525 nm (           ) were used and the emission wavelength was set to 
670 nm in order to avoid membrane fluidity artifacts (Clarke & Kane, 1997; Gross et al., 1994). 
Additionally, a large excess of lipid relative to the probes’ quantity has to be used to ensure that the 
probe itself does not modify the dipole potential significantly (Clarke & Kane, 1997; Wang, 2012). The 
variation of the intensities ratio,  , with the peptide concentration can be analyzed by a single binding 
site model (Cladera & O’Shea, 1998): 
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with the   values normalized for the value in the absence of the peptide,   .      is the asymptotic 
minimum value of   and    is the dissociation constant. 
For a better observation of the excitation spectra shifts, data can be transformed in differential spectra 
by subtracting the normalized excitation spectra of the probe without the interacting peptide and the 
spectra in its presence. A sinusoidal curve with one minimum and one maximum, cutting across the   
axis is obtained, as exemplified in Figure 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.4 - Representation of membrane dipole potential probed by di-8-ANEPPS. 
The excitation spectrum of membrane-bound di-8-ANEPPS shifts in response to changes in the 
dipole potential. The differential spectra help to visualize these shifts and to determine the 
wavelengths of maximal variation, in order to define the ratio R. Reprinted from (Matos et al., 2010b) 
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As indicated before, the ratio of intensities, , is calculated by the quotient of the values at two 
wavelengths of the differential spectra. An increase in dipole potential leads to a blue shift in the 
excitation spectrum, resulting in an increased ratio value. Conversely, the decreasing potential leads 
to a red shift and a consequent decrease of the ratio. If the dipole potential remains unchanged, as 
there is no interaction between the peptide and the membrane, a shift in the excitation spectra is not 
expected.  
 
Membrane dipole potential on LUV 
In order to assess membrane dipole potential, LUV were labeled with the probe di-8-ANEPPS. A 
solution containing 500 μM of freshly prepared liposomes were incubated overnight with di-8-ANEPPS 
10 μM, to maximize the incorporation of the probe in the membrane. Prior to fluorescence 
measurements, each peptide, yielding a final concentration within a range of 0-7 μM, was incubated 
with di-8-ANEPPS-labeled LUV for 1 h at room temperature. Excitation spectra and the ratio of 
intensities at the excitation wavelengths of 455 and 525 nm (           ) were obtained with the 
emission wavelength of 670 nm. Excitation and emission slits were set to 5 and 10 nm, respectively. 
As a control, liposomes incubated with ethanol instead of di-8-ANEPPS were also included. 
 
Membrane dipole potential on biological samples 
Erythrocytes 
A 1% hematocrit suspension of erythrocytes in HEPES buffer supplemented with 0.05% Pluronic F-
127, from a previously prepared 10% hematocrit sample, was used for labeling with di-8-ANEPPS 10 
μM. The suspension was incubated at room temperature for 1 h, with gentle agitation and protected 
from light. In order to remove unbound di-8-ANEPPS, two wash cycles were performed with 
centrifugations at 1500 g for 5 min. 
T20* and its derivatives, with a final concentration ranging from 0 to 6 μM, were incubated with 
erythrocytes at 0.02% hematocrit for 1 h and at room temperature, before fluorescence 
measurements. The experimental conditions of fluorescence measurements were identical to those 
previously described for LUV. 
 
Peripheral blood mononuclear cells (PBMC) 
PBMC were counted in a Moxi Z Mini Automated Cell Counter (ORFLO Technologies, Ketchum, ID, 
USA) and were prepared with a final concentration of 3000 cells/mL in 0.05% Pluronic F-127 
supplemented HEPES buffer, with di-8-ANEPPS 3.3 mM. Cells’ incubation with the fluorescent probe 
was performed during 1 h, at room temperature and protected from light. Unbound probe was washed 
twice with working buffer, with centrifugations at 1000 g for 5 min. 
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A concentration of 100 cells/μL was used to incubate PBMC with different concentrations of each 
peptide, within a range of 0-6 μM, for 1 h at room temperature. The experimental conditions of 
fluorescence measurements were identical to those previously described for LUV. 
The variation of   with the peptide concentrations for the different types of biomembranes was 
analyzed by a single binding model. 
 
Fluorescence quenching 
Fluorescence quenching refers to any process that decreases the fluorescence intensity of a given 
substance. An array of molecular interactions such as energy transfer, ground-state complex 
formation, molecular rearrangements, excited-state reactions or collisional quenching can result in the 
decrease of a molecules’ fluorescence intensity (Lakowicz, 2006). A quenching process, either static 
or dynamic, can occur if the fluorophore and the quencher are in contact with each other. In dynamic 
or collisional quenching, the quencher has to diffuse to the fluorophore during the lifetime of the 
excited state and, upon contact, the fluorophore returns to the ground state without emission of a 
photon. In static quenching, the fluorophore and quencher form a nonfluorescent complex. This 
molecular contact requirement allows the use of quenching experiments to disclose the accessibility of 
fluorophores to quenchers and, therefore, reveal the localization of fluorophores in proteins and 
membranes. If the fluorophore is located in the interior of a macromolecule, the quencher is unable to 
establish contact and neither collisional nor static quenching can occur (Lakowicz, 2006). 
Fluorescence’s collisional quenching is described by the Stern-Volmer equation: 
 
  
 
                  (2.8) 
 
 
where I0 and I are the fluorescence intensities in the absence and presence of quencher, respectively, 
Ksv is the Stern-Volmer constant and [Q] the concentration of quencher (Lakowicz, 2006). Low values 
of Ksv usually indicate that the fluorophore is inaccessible to water soluble quenchers and a higher 
value of this constant is an indication that the fluorophore is reachable; it could be free in solution or 
on the surface of a macromolecule.  
 
Quenching by acrylamide 
Acrylamide is a known quencher for tryptophan residues accessible to the aqueous environment and 
is useful to determine its surface accessibility. The emission spectra of 10 μM of T20* and its 
derivatives, incubated with POPC:Chol (2:1) liposomes with a final concentration of 3 mM, was 
obtained in the presence of acrylamide with a concentration ranging from 0-60 mM. An incubation time 
of 10 min was allowed before measurement. The same procedure was carried in the absence of LUV. 
An excitation wavelength of 290 nm was used in order to promote a selective excitation of tryptophan 
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residues. As the concentration of quencher increases, some artifacts may arise; acrylamide also 
absorbs at the exciting light, thus an increasing fraction of light is absorbed by the quencher and, 
because the overall absorption by the sample is increased, the penetration of the exciting light is less 
efficient, leading to a decreased fluorescence emission detection. For this reason, a correction of the 
fluorescence intensities by a correction factor, CF, is necessary (Coutinho & Prieto, 1993):  
 
   
    
    
 (
         
         
)       (2.9) 
 
where AbsT is the absorbance of the total solution and AbsF is the absorbance of the fluorophore at the 
initial concentration. Absorption measurements were performed on a Genesys 10S UV-Vis 
spectrophotometer (Thermo Fisher Scientific, Madison, WI, USA) at 290 nm. 
Quenching data were analyzed using the Stern-Volmer equation.  
 
Quenching by 5NS and 16NS 
Fluorescence quenching can also be a valuable tool to evaluate the depth of insertion in the 
membrane of a fluorophore, as an accurate determination of this parameter is an important step in 
protein and peptide-membrane interactions (Ladokhin, 2014). This can be achieved using steric acid 
molecules with doxyl (quencher) groups attached at different positions, such as 5-doxyl-stearic acid 
(5NS) and 16-doxyl-stearic acid (16NS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 - Representation of a lipid membrane (phospholipids in black) 
with incorporated 5NS (blue) and 16NS (red). 
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As depicted in Figure 2.5, 5NS, a stearic acid with the doxyl group at carbon 5 is a better quencher for 
molecules in a shallow position, close to the lipid-water interface, while 16NS, a molecule with the 
doxyl group attached to carbon 16, is expected to quench preferentially molecules buried deeply in the 
membrane (Fernandes et al., 2002). 
An identical procedure to the quenching by acrylamide was used: a solution of each peptide (10 μM) 
was incubated with 3 mM POPC:Chol (2:1) LUV and successive additions of small volumes of 5NS or 
16NS were made. The effective concentration of quencher at the membrane level was determined 
from the partition coefficient of both lipophilic molecules to biomembranes (Santos et al., 1998), and 
range from 0 to ≈ 0.6 M. For every addition, a 10 min incubation time was allowed before 
measurement. The same lipid suspension was used in both cases. 
Steady-state fluorescence measurements were carried out with a λexc of 280 nm and the emission 
spectra were recorded between 310 and 450 nm. The SIMEXDA method (Fernandes et al., 2002) was 
applied to obtain the depth of Trp insertion in the membrane.  
 
With the exception of ANS fluorescence, all fluorescence measurements mentioned above were 
conducted in a Varian Cary Eclipse fluorescence spectrophotometer (Mulgrave, Australia), with a 
controlled temperature of 25 ºC.  
The fitting of the equations to the experimental data was done using GraphPad Prism 5. 
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3. Results and discussion 
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In previous works, it was demonstrated that the addition of a lipid moiety to a fusion inhibitor peptide 
increased its efficiency towards HIV-1 inhibition (Augusto et al., 2014; Hildinger et al., 2001; Hollmann 
et al., 2013; Ingallinella et al., 2009). Taking this into account, a previous assessment of the antiviral 
activity was obtained through collaboration with Prof. Matteo Porotto (Departments of Pediatrics and of 
Microbiology and Immunology, Weill Medical College of Cornell University, New York, USA). The 
conjugated peptides presented an increased antiviral activity, with an approximately 280-fold decrease 
of the half maximal inhibitory concentration (IC50) relative to the unconjugated peptide, T20*. The 
antiviral activity parameters for U87 cell line, viral strain SF162 are listed in Table 3.1. 
 
 
Table 3.1 – Antiviral activity of different 
HIV-1 fusion inhibitors (U87 cell line; viral 
strain SF162). 
 
Fusion inhibitor IC50 (nM) 
T20* 640 
T20*-Chol 2.28 
T20*-PEG4-Chol 21.8 
T20*-PEG4-Palm 2.44 
T20*-Toco 6.44 
T20*-PEG4-Toco 2.48 
 
 
It was reported that the addition of a cholesterol moiety to enfuvirtide decreased its antiviral affinity, 
suggesting that an interference between the lipid moiety and the intrinsic LBD of enfuvirtide occurs 
(Ingallinella et al., 2009). The only difference between enfuvirtide-Chol and T20*-Chol is the peptide-
lipid linker: enfuvirtide-Chol has a 4 amino acid linker while T20*-Chol has a 6 amino acid one.      
T20*-Chol presents the highest antiviral activity, which suggests that the 6 amino acid linker may 
reduce the propensity to LBD-lipid moiety interferences. 
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3.1. Peptide aggregation 
The conjugation of peptides with lipid moieties may increase their susceptibility to aggregate in 
aqueous solution. For that reason, peptide aggregation was followed by ANS fluorescence. 
 
In the presence of hydrophobic regions, ANS fluorescence emission shifts to lower wavelengths (blue 
shift). A blue shift is observed in the ANS’ maximum fluorescence emission for all conjugated peptides 
(Figure 3.1), which indicates the presence of aggregates in solution. Conversely, T20* does not seem 
to aggregate upon increasing its concentration. In its sequence, T20* has charged residues 
intercalated with hydrophobic ones (Figure 2.1 – Materials and methods), which can prevent its 
aggregation in aqueous solution. To quantitatively differentiate the aggregation of the conjugated 
peptides, a fitting of the normalized fluorescence intensity data was performed (Figure 3.2). Fitting 
parameters are summarized in Table 3.2. 
 
 
 
 
 
 
Figure 3.1 - Fluorescence spectra of ANS titrated with T20* and its derivatives. 
ANS fluorescence spectra undergo a blue-shift with increasing peptide concentration (represented by the arrows). 
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Table 3.2 – Slope, intercept and R
2
 values determined from the linear fit of 
ANS fluorescence intensity vs. peptide concentration data.  
The slope (m), intercept (b) and the square of the correlation coefficient (R
2
) of the fit are 
represented for each peptide. The values represent mean ± SEM. 
 
Peptide m b R
2
 
T20* 0.0404 ± 0.00261 1.042 ± 0.0109 0.914 
T20*-Chol 0.216 ± 0.00831 1.087 ± 0.0343 0.969 
T20*-PEG4-Chol 0.278 ± 0.00538 1.103 ± 0.0222 0.992 
T20*-PEG4-Palm 0.177 ± 0.00451 1.054 ± 0.0186 0.986 
T20*-Toco 0.213 ± 0.00871 1.064 ± 0.0359 0.965 
T20*-PEG4-Toco 0.261 ± 0.00775 1.100 ± 0.0312 0.981 
 
The slope of the fit confirms that T20* is the least prone to aggregation. Conversely, although all 
conjugated peptides tend to form aggregates, T20*-PEG4-Chol and T20*-PEG4-Toco have the highest 
propensity. Although previous studies have reported that the PEG spacer improved substantially 
peptide solubility in aqueous media (Porotto et al., 2010), this feature was not observed for T20* 
conjugates. 
 
3.2. Membrane partition 
The evaluation of fusion inhibitor peptides’ interaction with membranes is a key aspect of their mode of 
action, since the efficiency of the drug can be correlated with the membranotropic properties of the 
peptide (Hollmann et al., 2013). Therefore the peptides’ partition to biomembrane model systems was 
assessed by means of peptide intrinsic fluorescence. Three membrane compositions were used: 
POPC, to mimic the fluidity properties of biological membranes, POPC:Chol (2:1), that mimics 
cholesterol-rich membranes, and POPC:Chol:SM (1:1:1), in order to replicate lipid rafts. 
Figure 3.2 – Dependence of fluorescence intensity with peptide concentration. 
For each peptide, a linear regression was applied to the variation of the ratio of the 
fluorescence intensity in the presence of the peptide (I) and in its absence (I0) with peptide 
concentration. Plotted values represent mean ± standard error of mean (SEM). 
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The partition coefficient, Kp, for each peptide was determined from the fitting of equation 2.5           
(see Materials and methods) rearranged, to the fluorescence intensities ratio (I /Iw) ratio vs. lipid 
concentration data. The Kp, and I /Iw values obtained are summarized in Table 3.3. 
 
 
 
 
 
 
 
 
 
Figure 3.3 – Partition of the peptides to lipid vesicles. 
Evaluation of Trp fluorescence variations of T20* derived peptides upon titration with large unilamellar vesicles 
(LUV), performed by successive additions of POPC (A), POPC:Chol (2:1) (B) and POPC:Chol:SM (1:1:1) (C) 
suspensions. Plotted values represent mean ± SEM. 
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Table 3.3 - Partition coefficients of different fusion inhibitor peptides. 
The partition coefficient (Kp) and I /Iw values were obtained from the fitting of the data obtained for T20* and its 
conjugates interaction with LUV of different compositions. 
a
 The type of partition curve obtained impairs the use of the equation. 
 
LUV Peptide Kp I /Iw 
POPC 
T20* 68.85 ± 42.00 3.521 ± 1.295 
T20*-Chol 149.3 ± 33.66 5.318 ± 0.7056 
T20*-PEG4-Chol 1037 ± 181.1 2.754 ± 0.1148 
T20*-PEG4-Palm 3417 ± 312.8 2.500 ± 0.03414 
T20*-Toco 132.8 ± 46.48 3.736 ± 0.7134 
T20*-PEG4-Toco 232.4 ± 35.81 4.132 ± 0.3100 
POPC:Chol 
(2:1) 
T20* ≈ 0 -- 
T20*-Chol 27.38 ± 38.19 11.22 ± 13.23 
T20*-PEG4-Chol 575.5 ± 69.56 3.318 ± 0.1315 
T20*-PEG4-Palm 537.4 ± 57.51 3.150 ± 0.1108 
T20*-Toco --
a
 -- 
T20*-PEG4-Toco 106.6 ± 29.60 5.799 ± 1.040 
POPC:Chol:SM 
(1:1:1) 
T20* ≈ 0 -- 
T20*-Chol 
--
a
 --
a
 
T20*-PEG4-Chol 
T20*-PEG4-Palm 
T20*-Toco 
T20*-PEG4-Toco 
 
 
In the presence of POPC vesicles, the fluorescence intensity of T20* and the conjugates increases, 
indicating that an interaction between the peptides and membrane takes place. In a previous work, it 
was reported that, for POPC membranes, enfuvirtide has a Kp of 1600 ± 100 (Veiga et al., 2004a), 
which is much higher than the obtained for T20* (Kp = 68.85 ± 42.00). Such difference may be due to 
the extra 6 amino acid residues of T20*, near to Trp rich region of the peptide, which may influence its 
partition to membranes.  
All conjugated peptides present considerably higher Kp values than T20*. PEG-containing peptides, 
especially T20*-PEG4-Chol and T20*-PEG4-Palm, have the highest values, which translates in a 
higher affinity of these peptides towards the membrane. Moreover, it could be expected that T20*-Chol 
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had a significantly higher Kp, which is not the case. This suggests that the tryptophan residues of the 
peptide are in a more hydrophilic environment.  
Similarly to what has been reported for enfuvirtide (Veiga et al., 2004a), peptides’ interaction is 
diminished in cholesterol containing membranes. Still, T20*-PEG4-Chol and T20*-PEG4-Palm have the 
highest Kp values, suggesting that PEG may potentiate membrane partition. 
Due to the type of partition curves obtained, it was not possible to determine the partition coefficients 
for POPC:Chol:SM membranes.  
T20*-Toco and T20*-PEG4-Toco interact with lower extent with POPC and POPC:Chol membranes 
and have the lowest antiviral activity amongst the conjugated peptides. Therefore, these peptides 
were not considered for further analysis. 
 
3.3. Membrane dipole potential 
In order to complement the membrane partition assays, which only follow the peptide Trp intrinsic 
fluorescence, peptide-membrane interaction was also evaluated by using the lipophilic probe di-8-
ANEPPS, a fluorescent probe sensitive to the membrane dipole potential of the membrane (Gross et 
al., 1994). The interaction of the peptides with LUV and human blood cells (PBMC and erythrocytes) 
was evaluated. Although peptide interaction with LUV can be characterized by their intrinsic 
fluorescence, this is impracticable with cells. As di-8-ANEPPS is an indirect reporter of the membrane 
dipole potential, any changes caused by the insertion or adsorption of the peptides can be translated 
in shifts in the probe’s excitation spectra. In order to facilitate the visualization of the spectral shifts, 
differential spectra were used. The differential spectra and binding profiles of T20* and its conjugated 
peptides to liposomes are presented in Figure 3.4.  
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A decrease in the dipole potential is characterized by the minimum of the differential spectra to be at 
lower wavelengths than its maximum. This change depends on the peptide and its concentration. As it 
can be seen in Figure 3.4 (A, B), all T20* conjugates have a higher influence in the membrane dipole 
potential than T20*, in good agreement with the partition data.  
In order to quantify the interaction between the peptides and the different lipid model systems, the 
ratio   was plotted as function of the peptide concentration (Figure 3.4 - C, D). Affinity constants can 
be determined by the fitting of equation 2.7 (Materials and methods) to the dipole variation curves. The 
obtained values are summarized in Table 3.4. 
 
 
 
 
Figure 3.4 - Fusion inhibitor interactions with di-8-ANEPPS labeled LUV. 
Differential spectra of POPC (A) and POPC:Chol (B) membrane-bound di-8-ANEPPS in the presence of T20*, 
T20*-Chol , T20*-PEG4-Chol and T20*-PEG4-Palm (5 μM). The binding profiles of T20* and conjugates to POPC 
(C) and POPC:Chol (D) are also represented, obtained by plotting the di-8-ANEPPS excitation ratio (Rnorm) as a 
function of peptide concentration. (Inset) Binding profile of T20* to POPC:Chol (D) with a lower range of the y axis.  
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Table 3.4 - Quantification of peptide binding to LUV. 
Comparison of the dissociation constant values, Kd, obtained from the binding profiles of T20* and conjugates 
with POPC and POPC:Chol, with the correspondent square of the correlation coefficient (R
2
) of the fitted curve. 
Values are presented as mean ± SEM.  
a
 The type of curve obtained impairs the use of the equation. 
 
Peptide 
POPC POPC:Chol 
Kd (μM) R
2
 Kd (μM) R
2
 
T20* --
a
 -- 2.79 ± 1.53 0.704 
T20*-Chol 2.06 ± 0.93 0.782 1.76 ± 0.23 0.970 
T20*-PEG4-Chol 6.45 ± 2.07 0.946 2.33 ± 0.23 0.985 
T20*-PEG4-Palm 5.12 ± 0.98 0.975 3.18 ± 0.40 0.980 
 
 
The conjugated peptides present lower Kd values than the unconjugated one for POPC vesicles, which 
suggest that the affinity towards membranes increase with the addition of a lipid moiety, in agreement 
with the partition data. Regarding to POPC:Chol vesicles, although T20* presents a higher Kd value 
than T20*-PEG4-Palm, and in spite of achieving a curve fit for the first (Figure 3.4, D - Inset), the 
correlation coefficient is fairly low (R
2 
= 0.704) and for that reason the estimated Kd value might not be 
reliable.  
Overall, the Kd value of all conjugated peptides decrease for POPC:Chol membranes in relation to 
POPC, suggesting a preference for cholesterol-rich membranes. Although these results are not in 
agreement with the partition data, it should be pointed that in the partition assays only the local 
changes on the Trp environment are monitored, and in this case this implies only the C-terminal region 
of the peptidic portion of inhibitors, whereas the dipole potential changes using di-8-ANEPPS labeled 
LUV are able to assess the interaction of the whole fusion inhibitor with the membrane. Thus, beside 
that from partition data it seems that in cholesterol-rich membranes the Trp residues are less involved 
in the interaction, that should not be treated as fewer interactions of the inhibitors with the membranes. 
An additional advantage of the dipole potential assays is that this methodology allows the evaluation 
of the direct interaction of the inhibitors with blood cells. In order to have a biological perspective of 
what may happen in the bloodstream, the interaction of the peptides with human PBMC and 
erythrocytes was studied (Figure 3.5). 
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Similarly to the data obtained for liposome membranes, all T20* conjugates seem to cause a more 
pronounced decrease in the membrane potential dipole than T20*. Affinity constants can be 
determined for the interaction of peptides with di-8-ANEPPS labeled blood cells, and the obtained 
results are summarized in Table 3.5. 
 
 
 
 
 
 
 
 
Figure 3.5 - Fusion inhibitor interactions with di-8-ANEPPS labeled cells. 
Differential spectra of PBMC (A) and erythrocytes (B) membrane-bound di-8-ANEPPS in the presence of T20*,    
T20*-Chol, T20*-PEG4-Chol and T20*-PEG4-Palm (4 μM). The binding profiles of T20* and conjugates to PBMC (C) 
and erythrocytes (D) are also represented and were obtained by the plotting the di-8-ANEPPS excitation ratio (Rnorm) 
as a function of peptide concentration. (Inset) Binding profile of T20* to PBMC (C) with a lower range on the y axis.  
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Table 3.5 - Quantification of peptide binding to blood cells. 
Comparison of the dissociation constant values, Kd, obtained by the binding profiles of T20* and conjugates to 
PBMC and erythrocytes, with the correspondent square of the correlation coefficient (R
2
) of the fitted curve. The 
values are presented as mean ± SEM.  
a
 The type of curve obtained impairs the use of the equation. 
 
Peptide 
PBMC Erythrocytes 
Kd (μM) R
2
 Kd (μM) R
2
 
T20* 2.86 ± 2.13 0.750 --
a
 -- 
T20*-Chol 0.239 ± 0.048 0.884 0.125 ± 0.020 0.931 
T20*-PEG4-Chol 0.309 ± 0.071 0.853 0.215 ± 0.030 0.943 
T20*-PEG4-Palm 0.181 ± 0.034 0.900 0.313 ± 0.027 0.978 
 
Concerning the interaction of the peptides with human blood cells, all conjugated peptides exhibit 
higher affinity than T20*. T20*-PEG4-Palm presents the highest affinity towards PBMC, while       
T20*-Chol has the highest affinity to interact with erythrocytes. Overall, the conjugated peptides 
present a higher affinity for erythrocytes when compared to PBMC. This reinforces that the peptides 
may interact preferentially with cholesterol containing membranes, since erythrocytes have 
cholesterol-rich membranes (Leidl et al., 2008). 
As these peptide drugs are expected to be injected, since oral administration should not be viable, 
peptide binding to blood cells has high relevance.  
One of HIV-1 main targets for replication and distribution all over the body are erythrocytes: it is known 
that the virus can associate with erythrocytes in vivo (Hess et al., 2002) and can bind to erythrocyte 
membrane in vitro (Beck et al., 2009). Moreover, trans-infection of other immune system cells present 
in the blood can be mediated by the erythrocytes-bound viruses (Banki et al., 2006; He et al., 2008a). 
For this reason, these cells with a pre-bound fusion inhibitor peptide could potentially restrict virus 
spreading through the body, and upon interaction, the virus itself could remain with the fusion peptide 
in its own membrane, since HIV virus and erythrocytes appear to have a similar membrane 
composition (Aloia et al., 1988). Moreover, PBMC, which include HIV-1 preferential target cells, 
contribute significantly to the virus replication as it has been reported that virus bound to the surface of 
cells remains infectious for T cells (Olinger et al., 2000). 
When injected, the fusion inhibitor peptides can be dissolved in the plasma, bound to plasma proteins, 
and also bound to cell membranes (Matos et al., 2010a). Therefore, concentrating antiretroviral 
peptides in cell membranes would enhance their availability towards the targets of the virus, 
increasing their efficiency and diminishing the amount of peptides bound to plasma proteins, which 
enhances drug clearance. 
The availability of the fusion inhibitor peptides can also be enhanced by the addition of a PEG 
molecule; however, and contrary to partition data, PEG-containing peptides present a lower affinity 
(higher Kd) than T20*-Chol towards erythrocytes, which might suggest that the PEG spacer does not 
influence membrane interaction. 
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3.4. Localization in the lipid bilayer 
In order to evaluate the location of the peptides in the membrane, we took the advantage of the 
quenching phenomena by using quenchers with different locations in the membrane. First, the 
accessibility of the tryptophan residues to the aqueous environment was evaluated by the 
fluorescence quenching of the peptides’ intrinsic fluorescence by acrylamide. As the conjugated 
peptides appear to have an higher affinity towards cholesterol-rich membranes, only POPC:Chol (2:1) 
membranes were considered. 
 
 
 
Figure 3.6 - Accessibility of the peptide to the aqueous environment. 
Stern-Volmer plots of T20* and its conjugates intrinsic fluorescence quenching by the increasing concentration of 
acrylamide, in the absence (Buffer) and presence of LUV (POPC:Chol). Plotted values represent mean ± SEM. 
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The Stern-Volmer constants were obtained by the fitting of equation 2.8 (Materials and methods) to 
the fluorescence data. 
 
Table 3.6 - Quantification of peptide binding. 
Comparison of the values of the Stern-Volmer constant, Ksv, values obtained for 
the quenching of T20* and conjugates intrinsic fluorescence by acrylamide in the 
absence (buffer) and presence (POPC:Chol) of lipid. The values are presented as 
mean ± SEM. 
 
Peptide 
Ksv (M
-1
) 
Buffer POPC:Chol 
T20* 14.63 ± 0.15 12.05 ± 0.16 
T20*-Chol 6.56 ± 0.13 -- 
T20*-PEG4-Chol 6.66 ± 0.18 -- 
T20*-PEG4-Palm 7.65 ± 0.08 3.40 ± 0.14 
 
 
Linear Stern-Volmer plots were obtained in the absence of lipid. By the Ksv values represented in 
Table 3.6, it is noticeable that the quenching of the conjugated peptides is less efficient than for T20*, 
which may indicate that the tryptophan residues are less exposed to the aqueous environment. Since 
conjugated peptides have lipid moieties in their structure and, as previously shown, all conjugated 
peptides exhibits a high tendency to aggregate, the formation of hydrophobic pockets may be the 
cause of such differences. In the presence of LUV, all fusion inhibitors demonstrate a reduced 
quenching phenomenon in comparison with the values in buffer. For the conjugated peptides 
containing cholesterol, T20*-Chol and T20*-PEG4-Chol, a non-linear Stern-Volmer plot was obtained 
in the presence of LUV. The shape of the curve indicates that the fluorescence intensity exhibit a 
slightly increase. This may be due to conformational alterations causing tryptophan residues to be less 
exposed, and therefore, acrylamide is unable to quench these residues. Both T20* and T20*-PEG4-
Palm present Ksv values lower than the assay in the absence of lipid, which is indicative that these 
peptides interact with the membrane, although T20* in a lower extent.  
The in-depth location of the tryptophan residues insertion in lipid membranes was evaluated by using 
lipophilic quenchers: 5NS and 16NS. The quencher group (doxyl) of these molecules, when inserted in 
the membrane, has distinct locations: the quencher group of 5NS locates at a shallow position, 
whereas 16NS quencher group locates near the hydrophobic core, deeply inside the membrane.  
The Stern-Volmer plots of the fluorescence quenching by the lipophilic probes of T20* and its 
conjugates are presented in Figure 3.7. 
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Overall, 5NS is a better quencher for all the T20* derived peptides, which suggests that the tryptophan 
residues are located in a shallow position of the membrane. 
By the application of the SIMEXDA method (Fernandes et al., 2002), the in-depth distribution of the 
fluorophores was obtained (Figure 3.8). 
 
 
 
 
 
 
 
 
 
Figure 3.7 - Fluorescence quenching by lipophilic probes. 
Stern-Volmer plots of the fluorescence quenching of T20* and its conjugates by the lipophilic quenchers 5NS and 
16NS in POPC:Chol LUV. Plotted values represent mean ± SEM. 
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A relatively shallow position is observed for T20* and conjugates. In average, T20* locates 13.0 Å 
away from the center of the bilayer, while T20*-PEG4-Palm locates at 14.6 Å. The conjugates with 
cholesterol, T20*-Chol and T20*-PEG4-Chol, locate at 15.4 Å and 15.6 Å, respectively. These results 
seem to disagree with the acrylamide quenching data for T20*, which suggest that the Trp residues 
are more exposed to the aqueous environment and, therefore, the location of the peptide is more 
superficial. However, the lipophilic probes 5NS and 16NS only act on peptides that are inserted in the 
membrane regardless of their concentration. Additionally, partition assays demonstrated that T20* 
interacts with the membrane in a low extent. Therefore, the 5NS and 16NS quenching data indicates 
that the small fraction of T20* that interacts with the membrane is inserted deeply in it.  Interestingly, 
beside lipid conjugation boost the membrane interaction, the conjugated peptides exhibit a more 
shallow position in the membrane, especially in the case of cholesterol as a lipid moiety. Furthermore, 
PEG addition seems to have a negligible effect on the peptide location, contrary to previous results 
with C34-Chol (Augusto et al., 2014). However, it should be pointed that in the case of the C34 
conjugated peptide, the Trp region is located in the opposite region relative to the lipid moiety. 
An interesting result is that T20*-Chol presented a lower membrane affinity than T20*-PEG4-Palm, but 
higher than T20*-PEG4-Chol. However, the cholesterol containing peptides are located in the same 
position and are more interfacial than T20*-PEG4-Palm, nevertheless T20*-Chol exhibit the best 
antiviral activity (Table 3.1). 
 
All this data confirms what was previously suggested (Augusto et al., 2014), that maximizing antiviral 
activity requires finding the proper balance of the membrane affinity and exposure of the peptide 
moiety, through variations in the lipid-binding domain. 
 
Figure 3.8 - Localization of T20* and its conjugates inside the membrane. 
Depth of insertion of the peptides in cholesterol-rich membranes, POPC:Chol (2:1), 
determined by the SIMEXDA method. The distributions’ half-width at half-height were 2 
Å for all peptides. The average location away from the center of the bilayer was 13 Å 
for T20* and 14.6 Å for T20*-PEG4-Palm. T20*-Chol and T20*-PEG4-Chol have a 
similar location of 15.4 Å and 15.6 Å, respectively. 
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4. Conclusion 
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The fusion process is a key step in HIV infection, which can be targeted by fusion inhibitor peptides. 
Currently, enfuvirtide is the only fusion inhibitor approved for HIV-1 treatment. However, the rapid 
development of viral strains resistant to this inhibitor triggered the development of new peptide 
antiviral drugs. Fusion inhibitor peptides bind to the NHR region of gp41 in the pre-bundle 
configuration, i.e., when the extended configuration of gp41 is bridging the viral and host membranes, 
before their fusion. Therefore, these peptides have a narrow time and space window of opportunity to 
bind to their target, which makes the aqueous diffusion of the peptide to their target less efficient. As 
previously reported (Franquelim et al., 2008; Hollmann et al., 2013; Veiga et al., 2004a, 2004b), 
lipophilicity is an important factor for antiviral activity, since it conditions the local concentration of the 
fusion inhibitors at the membrane level. High antiviral activity and membranotropic behavior are 
related to each other, showing that the plasma membrane has an important role during the inhibition 
process mediated by the fusion inhibitor peptides. One of the strategies to improve the fusion 
inhibitors’ binding to the membrane is the addition of lipid moieties to fusion peptides. This can 
improve the antiviral activity of fusion inhibitors, since the peptide is already present in the membrane 
when the virus interacts with the host cells. In previous works, it was reported that the addition of a 
cholesterol moiety to a fusion inhibitor, such as C34, improved its membrane interaction (especially 
with those containing cholesterol), and therefore its antiviral potency. 
In this work, the interaction of enfuvirtide-derived peptides, by the conjugation with lipid anchors and 
using PEG and 6 additional amino acid residues in between, towards biomembrane model systems 
and human blood cells as a biological model for what may happen in the bloodstream, was assessed. 
The addition of lipid moieties to T20* increased its antiviral potency, and partition data showed that 
there were also an increased binding of all conjugated peptides to membranes. However, a detailed 
analysis of the partition data towards membranes with different compositions reveals differences 
between the conjugated peptides. Besides, and in all the cases, conjugated peptides exhibit higher 
partition coefficients than T20*. Kp values decreased when cholesterol membranes were tested, 
meaning that the tryptophan region is less involved in the membrane interaction in those compounds. 
In order to complement partition data, fusion inhibitors interaction with membranes were also 
evaluated following the dipole potential changes using di-8-ANEPPS labeled LUV. Unlike the behavior 
observed with partition assays, T20* and its conjugates decreased in a greater extent the membrane 
dipole potential of POPC:Chol membranes, when compared with POPC. As lipid rafts are essential for 
the HIV entry process, the high affinity of T20* conjugates towards cholesterol-rich domains would 
concentrate the drug where HIV fusion is likely to occur. Erythrocytes and PBMC are the main targets 
of the virus for distribution and replication all over the body, respectively. In this context, the 
interactions of inhibitors with these two types of cells were also evaluated by measuring dipole 
potential changes. Similarly to LUV results, T20* conjugates presented a higher affinity than 
unconjugated T20* for both human blood cells.  
Overall, fluorescence quenching assays revealed that T20* conjugated peptides interact with 
POPC:Chol membranes and their tryptophan residues locate in a more shallow position within the 
membrane than the unconjugated peptide. These fluorophores are more exposed to the aqueous 
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environment, and therefore the peptidic portion of the inhibitors is more available to interact with the 
virus.  
Regarding the different lipid moieties tested, besides all of them being able to boost membrane 
affinity, cholesterol seems to be the one that provides the best balance between membrane anchoring 
and exposure. Additionally, although it has been reported that PEG addition to fusion inhibitors 
increases its antiviral activity and affinity towards membranes, the results obtained here were 
inconclusive at that level. 
Although a further characterization of the peptides’ membranotropic properties is necessary, the 
results obtained allow to conclude that a proper balance between membrane affinity and exposure of 
the peptide is required in order to enhance antiviral activity. The addition of lipid moieties to an 
established fusion inhibitor, such as enfuvirtide, can be a promising strategy against HIV. 
 
 
 
 
 
 
´ 
  
Figure 3.9 - Putative role of action of HIV-1 fusion inhibitors T20*-Chol and T20*-PEG4-Chol. 
T20* lipid conjugated peptides anchor to the membrane via their cholesterol moiety. In the context of HIV-1 gp41 
engagement with the target cell, a confined space exists between the two membranes. The drug concentrated in 
the lipid raft environment may reach its target (gp41 during its extended conformation) more efficiently than 
simple diffusion in aqueous solution. Moreover, the anchoring promoted by the cholesterol at the C-terminal and 
the higher exposition of the PBD to aqueous media, brings the peptide into contact in the correct orientation to 
compete with the NHR binding site. This way, gp41 mediated fusion may be inhibited, blocking viral content entry 
into the cell. 
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